Herbal medicine Gan‑fu‑kang downregulates Wnt/Ca2+ signaling to attenuate liver fibrogenesis invitro and invivo.

Abstract

The present study was designed to verify the effect of the Chinese prescription Gan‑fu‑kang (GFK) on the treatment of liver fibrosis, and to investigate its underlying mechanisms. Liver fibrosis was established in rats by the subcutaneous administration of 0.5mg/kg carbon tetrachloride (CCl4) twice a week for 8weeks. Subsequently, the rats were divided into four CCl4 groups, which were treated daily with vehicle and GFK (31.25, 312.5 and 3,125mg/kg/day) orally between weeks9 and 20. The inhibitory action of GFK‑medicated serum on platelet‑derived growth factor (PDGF)‑stimulated HSC‑T6 cells was also investigated. Biochemical parameters, hydroxyproline (Hyp) content and histological changes to the liver were measured. Reverse transcription‑quantitative polymerase chain reaction, western blotting and immunohistochemistry were used to examine the expression of α‑smooth muscle actin (α‑SMA), PDGF‑BB, PDGF receptorβ, collagen typeIandII, and the Wnt/Ca2+ signaling pathway. The results showed that GFK significantly alleviated the histological changes, decreased the content of Hyp in the liver and improved liver function in rats. In addition, GFK and GFK‑medicated serum effectively inhibited collagen deposition, reduced the expression of α‑SMA and downregulated the Wnt/Ca2+ signaling pathway invivo and invitro, respectively, as well as cell viability (P<0.05). These results indicated that GFK was effective in attenuating liver injury and fibrosis through downregulation of the Wnt/Ca2+ signaling pathway.